Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx Inc (NASDAQ: CVRX) is a medical device company focused on neuromodulation technology for cardiovascular disease. The company develops and commercializes the Barostim system, an implantable device that treats heart failure and resistant hypertension by stimulating the body's natural blood pressure regulation mechanisms.
This news feed covers developments relevant to CVRx investors and healthcare professionals tracking the company's commercial progress. As a single-product medical device company in the growth phase, CVRx news typically centers on quarterly financial results, clinical data presentations, reimbursement updates, and investor conference appearances. Earnings reports provide insight into Barostim procedure volumes and revenue trends, while conference presentations often include management commentary on commercial strategy and market expansion.
Given CVRx's position in the cardiovascular device space, news may also include clinical study updates that demonstrate Barostim outcomes, regulatory developments affecting device reimbursement, and broader healthcare policy changes impacting medical device adoption. The company's participation at major healthcare investor conferences such as J.P. Morgan Healthcare Conference and specialty medical meetings provides regular updates on business progress.
Bookmark this page to follow CVRx developments as the company works to expand Barostim adoption among cardiologists, electrophysiologists, and heart failure specialists across the United States healthcare system.
CVRx (NASDAQ: CVRX) confirmed that Category I CPT codes for baroreflex activation therapy using its Barostim device replaced Category III codes effective Jan 1, 2026. Category I CPT codes indicate an established procedure and can support broader adoption, coverage, and reimbursement across the U.S. healthcare system.
CVRx said U.S. hospitals and physicians should update billing systems and begin using the new codes for procedures performed on or after Jan 1, 2026. The company stated it believes the change will enable more predictable and consistent reimbursement for Barostim patients and providers.
CVRx (NASDAQ: CVRX) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The presentation begins at 3:45 p.m. PT and will be available via live webcast at the company's investor site. An archived recording will be posted after the live event and accessible at the same URL for a limited time.
This is a company investor presentation and not an earnings release or regulatory filing.
CVRx (NASDAQ: CVRX) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025.
The session is scheduled for 2:00 p.m. ET and will be available via a live audio webcast on the company investor relations website at ir.cvrx.com. The presentation offers investors a chance to hear management discuss recent developments and company outlook.
CVRx (NASDAQ: CVRX) reported third-quarter 2025 results: revenue $14.7M (+10% YoY) with U.S. revenue $13.5M (+10% YoY) and 250 active U.S. implanting centers. Gross profit was $12.8M (+15% YoY) and gross margin 87% (up from 83%). Net loss narrowed slightly to $12.9M (−$0.2M) or $0.49 per share. Cash and cash equivalents totaled $85.1M. CMS finalized Category I CPT coding, which management cites as improving patient access and reducing adoption barriers. Full‑year 2025 guidance was updated to $55.6M–$56.6M revenue, 85%–86% gross margin, and $98M–$99M operating expenses. The company expects Q4 2025 revenue of $15.0M–$16.0M.
CVRx (NASDAQ: CVRX) announced that management will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov 18, 2025.
The presentation is scheduled for 8:00 a.m. GMT / 4:00 a.m. ET and will be available live via audio webcast on the company investor relations site at ir.cvrx.com.
CVRx (NASDAQ: CVRX) will release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The company will host a conference call to review results on Nov. 5, 2025 at 4:30 p.m. Eastern Time.
A live webcast will be available at the company investor relations page (ir.cvrx.com). U.S. telephone dial-in is 1-877-704-4453; international dial-in is 1-201-389-0920. Callers are asked to dial in approximately ten minutes before the start time.
CVRx (NASDAQ: CVRX) reported its Q2 2025 financial results, achieving total revenue of $13.6 million, up 15% year-over-year. The company's U.S. Heart Failure revenue reached $12.1 million, also growing 15%. Active U.S. implanting centers increased 27% to 240 centers.
Key developments include CMS's proposal to maintain Barostim in APC 1580 for 2026 with a $45,000 outpatient procedure payment, favorable physician fee proposals for Category I CPT codes, and the appointment of Brent Binkowski as COO. The company narrowed its FY2025 guidance to $55.0-$57.0 million in revenue with 83-84% gross margin.
Despite revenue growth, CVRx reported a net loss of $14.7 million ($0.57 per share) and held $95.0 million in cash and equivalents as of June 30, 2025.
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 3:00 PM ET.
Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time to discuss the results. Investors can access the call via telephone using the conference ID CVRXQ225 or through a live webcast available on the company's investor relations website at ir.cvrx.com.
[]CVRx (NASDAQ: CVRX) announced that CMS has proposed to maintain Barostim implant procedures in the New Technology APC 1580, with an approximate payment of $45,000 for outpatient procedures. This follows two significant reimbursement developments: Barostim's assignment to a higher-paying MS-DRG for inpatient procedures (October 2024) and its transition from Category III to Category I CPT codes for physician payments (effective January 2026).
The final 2026 Medicare Hospital OPPS rule is expected in November 2025, with implementation planned for January 2026. These reimbursement updates validate Barostim's clinical value in treating heart failure patients with reduced ejection fraction.
FAQ
What is the current stock price of Cvrx (CVRX)?
What is the market cap of Cvrx (CVRX)?
